Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Antipsychotic Drugs and Risk of Developing Venous Thromboembolism and Pulmonary Embolism: A Systematic Review and Meta-Analysis

Author(s): Omid Arasteh, Homa Nomani, Hamed Baharara, Seyed A. Sadjadi, Amir H. Mohammadpour*, Vahid Ghavami*, Thozhukat Sathyapalan and Amirhossein Sahebkar*

Volume 18, Issue 6, 2020

Page: [632 - 643] Pages: 12

DOI: 10.2174/1570161118666200211114656

Price: $65

Abstract

Background: Antipsychotic (AP) medications are the cornerstone treatment for schizophrenia and some other psychiatric diseases. However, some observational studies suggest that these medications might increase the risk of venous thromboembolism (VTE) and pulmonary embolism (PE).

Objectives: The aim of this study was to assess whether AP medications are associated with the development of VTE or PE, and to assess the risk based on any type of AP drugs, quality of studies and after adjustment of risk factors.

Data Sources: To identify relevant studies, we searched PubMed and EMBASE databases up to February 2019. We also searched the reference lists of relevant articles for related studies.

Study Selection: Twenty studies fulfilled the eligibility criteria and were included in our meta-analysis after screening relevant observational cohort and case-control studies.

Primary Outcome: The primary outcome of our meta-analysis was the occurrence of all VTE or PE only attributed to exposure to AP medications compared with non-exposure to AP medications.

Results: Exposure to AP drugs was associated with a significant increase in the risk of VTE (RR 1.53, 95% CI 1.30-1.80, I2 = 85%) and PE (RR 3.69, 95% CI 1.23-11.07, I2 = 90%). In the subgroup metaanalysis, the use of low-potency AP drugs was associated with a higher risk of VTE, (RR 1.90, 95% CI 1.04-3.47, I2 = 78%).

Conclusion: AP exposure was associated with a 1.5-fold increase in the risk of VTE and a 3.7-fold increase in the risk of PE. Low-potency AP drugs were associated with a higher risk of VTE. However, high heterogeneity among studies limits the generalizability of the results.

Keywords: Antipsychotics, venous thromboembolism, pulmonary embolism, meta-analyses, antipsychotics drugs, psychiatric disorders.

« Previous Next »
Graphical Abstract

[1]
Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379(9831): 2063-71.
[http://dx.doi.org/10.1016/S0140-6736(12)60239-6] [PMID: 22560607]
[2]
Amato D, Canneva F, Cumming P, et al. A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter. Mol Psychiatry 2018; 23: 1-8.
[http://dx.doi.org/10.1038/s41380-018-0114-5] [PMID: 30038229]
[3]
Harvey RC, James AC, Shields GE. A systematic review and network meta-analysis to assess the relative efficacy of antipsychotics for the treatment of positive and negative symptoms in early-onset schizophrenia. CNS Drugs 2016; 30(1): 27-39.
[http://dx.doi.org/10.1007/s40263-015-0308-1] [PMID: 26801655]
[4]
Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull 2015; 114(1): 169-79.
[http://dx.doi.org/10.1093/bmb/ldv017] [PMID: 25957394]
[5]
Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag 2017; 13: 757-77.
[http://dx.doi.org/10.2147/TCRM.S117321] [PMID: 28721057]
[6]
Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf 2017; 40(9): 771-81.
[http://dx.doi.org/10.1007/s40264-017-0543-0] [PMID: 28585153]
[7]
Jönsson AK, Schill J, Olsson H, Spigset O, Hägg S. Venous thromboembolism during treatment with antipsychotics: a review of current evidence. CNS Drugs 2018; 32(1): 47-64.
[http://dx.doi.org/10.1007/s40263-018-0495-7] [PMID: 29423659]
[8]
Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis 2016; 41(1): 3-14.
[http://dx.doi.org/10.1007/s11239-015-1311-6] [PMID: 26780736]
[9]
Di Nisio M, van Es N, Büller HR. Deep vein thrombosis and pulmonary embolism. Lancet 2016; 388(10063): 3060-73.
[http://dx.doi.org/10.1016/S0140-6736(16)30514-1] [PMID: 27375038]
[10]
Barbui C, Conti V, Cipriani A. Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studies. Drug Saf 2014; 37(2): 79-90.
[http://dx.doi.org/10.1007/s40264-013-0127-6] [PMID: 24403009]
[11]
Zhang R, Dong L, Shao F, Tan X, Ying K. Antipsychotics and venous thromboembolism risk: a meta-analysis. Pharmacopsychiatry 2011; 44(5): 183-8.
[http://dx.doi.org/10.1055/s-0031-1280814] [PMID: 21739416]
[12]
Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 2000; 356(9237): 1219-23.
[http://dx.doi.org/10.1016/S0140-6736(00)02784-7] [PMID: 11072939]
[13]
Mollard LM, Le Mao R, Tromeur C, et al. Antipsychotic drugs and the risk of recurrent venous thromboembolism: A prospective cohort study. Eur J Intern Med 2018; 52: 22-7.
[http://dx.doi.org/10.1016/j.ejim.2018.02.030] [PMID: 29548526]
[14]
Nakamura M, Yamada N, Oda E, et al. Predictors of venous thromboembolism recurrence and the bleeding events identified using a Japanese healthcare database. J Cardiol 2017; 70(2): 155-62.
[http://dx.doi.org/10.1016/j.jjcc.2016.10.012] [PMID: 28245956]
[15]
Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic medication and venous thrombosis. Br J Psychiatry 2001; 179: 63-6.
[http://dx.doi.org/10.1192/bjp.179.1.63] [PMID: 11435271]
[16]
Agresti A. An introduction to categorical data analysis. 3rd ed. New Jersey: Wiley Press 2018; p. 102.
[17]
Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study. BMJ 2011; 343: d4656.
[http://dx.doi.org/10.1136/bmj.d4656] [PMID: 21846713]
[18]
Liperoti R, Pedone C, Lapane KL, Mor V, Bernabei R, Gambassi G. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 2005; 165(22): 2677-82.
[http://dx.doi.org/10.1001/archinte.165.22.2677] [PMID: 16344428]
[19]
Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987; 9: 1-30.
[http://dx.doi.org/10.1093/oxfordjournals.epirev.a036298] [PMID: 3678409]
[20]
Schmedt N, Garbe E. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients with dementia. J Clin Psychopharmacol 2013; 33(6): 753-8.
[http://dx.doi.org/10.1097/JCP.0b013e3182a412d5] [PMID: 24052055]
[21]
Kleijer BC, Heerdink ER, Egberts TC, Jansen PA, van Marum RJ. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients. J Clin Psychopharmacol 2010; 30(5): 526-30.
[http://dx.doi.org/10.1097/JCP.0b013e3181f0e87d] [PMID: 20814323]
[22]
Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ 2010; 341: c4245.
[http://dx.doi.org/10.1136/bmj.c4245] [PMID: 20858909]
[23]
Wang MT, Liou JT, Huang YW, et al. Use of antipsychotics and risk of venous thromboembolism in postmenopausal women. A population-based nested case-control study. Thromb Haemost 2016; 115(6): 1209-19.
[http://dx.doi.org/10.1160/TH15-11-0895] [PMID: 26941052]
[24]
Conti V, Venegoni M, Cocci A, Fortino I, Lora A, Barbui C. Antipsychotic drug exposure and risk of pulmonary embolism: a population-based, nested case-control study. BMC Psychiatry 2015; 15: 92.
[http://dx.doi.org/10.1186/s12888-015-0479-9] [PMID: 25924683]
[25]
Ishiguro C, Wang X, Li L, Jick S. Antipsychotic drugs and risk of idiopathic venous thromboembolism: a nested case-control study using the CPRD. Pharmacoepidemiol Drug Saf 2014; 23(11): 1168-75.
[http://dx.doi.org/10.1002/pds.3699] [PMID: 25195779]
[26]
Jönsson AK, Horváth-Puhó E, Hägg S, Pedersen L, Sørensen HT. Antipsychotics and risk of venous thromboembolism: A population-based case-control study. Clin Epidemiol 2009; 1: 19-26.
[http://dx.doi.org/10.2147/CLEP.S4969] [PMID: 20865083]
[27]
Allenet B, Schmidlin S, Genty C, Bosson JL. Antipsychotic drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf 2012; 21(1): 42-8.
[http://dx.doi.org/10.1002/pds.2210] [PMID: 22052683]
[28]
Ray JG, Mamdani MM, Yeo EL. Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism. Thromb Haemost 2002; 88(2): 205-9.
[PMID: 12195690]
[29]
Duval S, Tweedie R. A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis. J Am Stat Assoc 2000; 95: 89-98.
[http://dx.doi.org/10.1080/01621459.2000.10473905]]
[30]
Jönsson AK, Brudin L, Ahlner J, Hedenmalm K, Eriksson A, Hägg S. Antipsychotics associated with pulmonary embolism in a Swedish medicolegal autopsy series. Int Clin Psychopharmacol 2008; 23(5): 263-8.
[http://dx.doi.org/10.1097/YIC.0b013e3282fe9d44] [PMID: 18703935]
[31]
Hamanaka S, Kamijo Y, Nagai T, et al. Massive pulmonary thromboembolism demonstrated at necropsy in Japanese psychiatric patients treated with neuroleptics including atypical antipsychotics. Circ J 2004; 68(9): 850-2.
[http://dx.doi.org/10.1253/circj.68.850] [PMID: 15329507]
[32]
Parkin L, Skegg DC, Herbison GP, Paul C. Psychotropic drugs and fatal pulmonary embolism. Pharmacoepidemiol Drug Saf 2003; 12(8): 647-52.
[http://dx.doi.org/10.1002/pds.841] [PMID: 14762980]
[33]
Lacut K, Le Gal G, Couturaud F, et al. Association between antipsychotic drugs, antidepressant drugs and venous thromboembolism: results from the EDITH case-control study. Fundam Clin Pharmacol 2007; 21(6): 643-50.
[http://dx.doi.org/10.1111/j.1472-8206.2007.00515.x] [PMID: 18034665]
[34]
Masopust J, Malý R, Urban A, Hosák L, Cermáková E. Antipsychotic drugs as a risk factor for venous thromboembolism. Int J Psychiatry Clin Pract 2007; 11(3): 246-9.
[http://dx.doi.org/10.1080/13651500601017357] [PMID: 24941366]
[35]
Dennis M, Shine L, John A, et al. Risk of adverse outcomes for older people with dementia prescribed antipsychotic medication: a population based e-cohort study. Neurol Ther 2017; 6(1): 57-77.
[http://dx.doi.org/10.1007/s40120-016-0060-6] [PMID: 28054240]
[36]
Ballard C, Isaacson S, Mills R, et al. Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson disease psychosis. J Am Med Dir Assoc 2015; 16(10): 898.
[http://dx.doi.org/10.1016/j.jamda.2015.06.021] [PMID: 26239690]
[37]
Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 2005; 3(8): 1611-7.
[http://dx.doi.org/10.1111/j.1538-7836.2005.01415.x] [PMID: 16102026]
[38]
Ronaldson KJ. Cardiovascular disease in clozapine-treated patients: evidence, mechanisms and management. CNS Drugs 2017; 31(9): 777-95.
[http://dx.doi.org/10.1007/s40263-017-0461-9] [PMID: 28808933]
[39]
Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. Hematology Am Soc Hematol Educ Program 2005; 1-12.
[http://dx.doi.org/10.1182/asheducation.V2005.1.1.1] [PMID: 16304352]
[40]
Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007; 21(11): 911-36.
[http://dx.doi.org/10.2165/00023210-200721110-00004] [PMID: 17927296]
[41]
Ageno W, Squizzato A, Garcia D, Imberti D. Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost 2006; 32(7): 651-8.
[http://dx.doi.org/10.1055/s-2006-951293] [PMID: 17024592]
[42]
Ishida T, Sakurai H, Watanabe K, Iwashita S, Mimura M, Uchida H. Incidence of deep vein thrombosis in catatonic patients: A chart review. Psychiatry Res 2016; 241: 61-5.
[http://dx.doi.org/10.1016/j.psychres.2016.04.105] [PMID: 27156025]
[43]
Urban A, Masopust J, Malý R, Hosák L, Kalnická D. Prolactin as a factor for increased platelet aggregation. Neuroendocrinol Lett 2007; 28(4): 518-23.
[PMID: 17693964]
[44]
Axelsson S, Hägg S, Eriksson AC, Lindahl TL, Whiss PA. In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation. Clin Exp Pharmacol Physiol 2007; 34(8): 775-80.
[http://dx.doi.org/10.1111/j.1440-1681.2007.04650.x] [PMID: 17600556]
[45]
De Clerck F, Somers Y, Mannaert E, Greenspan A, Eerdekens M. In vitro effects of risperidone and 9-hydroxy-risperidone on human platelet function, plasma coagulation, and fibrinolysis. Clin Ther 2004; 26(8): 1261-73.
[http://dx.doi.org/10.1016/S0149-2918(04)80097-3] [PMID: 15476907]
[46]
Shen H, Li R, Xiao H, Zhou Q, Cui Q, Chen J. Higher serum clozapine level is associated with increased antiphospholipid antibodies in schizophrenia patients. J Psychiatr Res 2009; 43(6): 615-9.
[http://dx.doi.org/10.1016/j.jpsychires.2008.09.009] [PMID: 18976782]
[47]
Halacheva K, Dimova S, Tolev T, Dimov D, Nikolova M. Elevated anticardiolipin antibodies in schizophrenic patients before and during neuroleptic medication. Psychiatry Res 2009; 169(1): 51-5.
[http://dx.doi.org/10.1016/j.psychres.2008.05.011] [PMID: 19596154]
[48]
Diaz FJ, Pérez-Iglesias R, Mata I, et al. Possible effects of some antipsychotic drugs on C-reactive protein in a drug-naïve psychotic sample. Schizophr Res 2010; 121(1-3): 207-12.
[http://dx.doi.org/10.1016/j.schres.2010.06.002] [PMID: 20580206]
[49]
Masopust J, Malý R, Andrýs C, Vališ M, Bažant J, Hosák L. Markers of thrombogenesis are activated in unmedicated patients with acute psychosis: a matched case control study. BMC Psychiatry 2011; 11: 2.
[http://dx.doi.org/10.1186/1471-244X-11-2] [PMID: 21199572]
[50]
Eldibany MM, Caprini JA. Hyperhomocysteinemia and thrombosis: an overview. Arch Pathol Lab Med 2007; 131(6): 872-84.
[PMID: 17550314]
[51]
Ishida T, Katagiri T, Uchida H, et al. Incidence of deep vein thrombosis in restrained psychiatric patients. Psychosomatics 2014; 55(1): 69-75.
[http://dx.doi.org/10.1016/j.psym.2013.04.001] [PMID: 23845320]

Rights & Permissions Print Cite
Article Metrics
32
© 2024 Bentham Science Publishers | Privacy Policy